ALTO-100, previously known as NSI-189 (NeuralStem Inc. 189), [3] is a drug described as a hippocampal neurogenesis stimulant and indirect brain-derived neurotrophic factor (BDNF) modulator which is under development for the treatment of major depressive disorder (MDD), bipolar depression, and post-traumatic stress disorder (PTSD).

2025年2月25日 · NSI-189, a neurogenic nootropic compound, functions as a potential cognitive enhancer through documented brain pathways. NSI-189 phosphate, its most studied form, has demonstrated promising results in research settings. NSI-189’s mechanisms target neural growth and brain function support, making it a notable subject in nootropic research circles.

NSI-189 是一個 實驗性藥物 （英语：experimental drug），由 Neuralstem, Inc. （英语：Neuralstem, Inc.） 開發的 抗抑鬱藥。 用於治療 重性抑郁障碍 （MDD）， 認知障礙 以及 神经退行性疾病。 [2][1][3] 相關研究由美國 國防高等研究計劃署 （DARPA）以及 國立衛生研究院 （NIH）出資。 [4] NSI-189的 作用機轉 為在 海馬迴 增強的 神經元新生 以及其體積的增大， [2] 但NSI-189達成此效果的機轉尚不明朗。 配體結合研究 （英语：ligand binding assay） 目前為止 …

These results suggest that NSI-189 is effective as a safe adjunctive therapy, with most compelling antidepressant and procognitive benefits noted in patients with moderate depression.

NSI-189 is a novel neurogenic compound independent of monoamine reuptake pathways. This trial evaluated oral NSI-189 as monotherapy in major depressive disorder. To improve signal detection, the...

Enhancing neurogenesis may be a powerful stroke therapy. Here, we tested in a rat model of ischemic stroke the beneficial effects of NSI‐189, an orally active, new molecular entity (mol. wt. 366) with enhanced neurogenic activity, and indicated as ...

Results from a preliminary proof of concept study suggests that NSI-189 may be capable of mitigating depressive symptoms and improve cognitive function in adults with DSM-5-defined Major Depressive Disorder (MDD). Expert opinion: Preliminary proof-of-concept studies indicate both antidepressant and procognitive effects.

NSI-189 is a novel, neurogenic compound independent of serotonin or norepinephrine reuptake inhibition pathways. The compound was discovered by systematic screening of a chemical library against in vitro model of HI neurogenesis using a stable cell line of human fetal HI neural stem cells (US Pat. No. 8,293,488; 7,650,533).

BACKGROUND NSI-189 phosphate (NSI-189) is a novel neurogenic molecule with pleiotropic properties, including antidepressant, procognitive, synaptoplastic, and neurotrophic activities demonstrated in preclinical studies. Its antidepressant activity is monoamine-independent.

2015年12月8日 · We wanted to examine tolerability and efficacy of NSI-189, a benzylpiperizine-aminiopyridine neurogenic compound for treating major depressive disorder (MDD). This was a Phase 1B, double blind,...